Management of liver diseases during the pandemic of coronavirus disease-19

키워드

참고문헌 (51)

1. Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
2. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280.e8 (2020)
3. Wong SH, "Covid-19 and the digestive system", J Gastroenterol Hepatol, 35, pp.744~748 (2020)
4. Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
5. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
6. Zhang C, "Liver injury in COVID-19 : management and challenges", Lancet Gastroenterol Hepatol, 5, pp.428~430 (2020)
7. Xu L, "Liver injury during highly pathogenic human coronavirus infections", Liver Int, 40, pp.998~1004 (2020)
8. Gu J, "COVID-19 : Gastrointestinal manifestations and potential fecal-oral transmission", Gastroenterology, 158, pp.1518~1519 (2020)
9. Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebocontrolled, multicentre trial", Lancet, 395, pp.1569~1578 (2020)
10. Beigel JH, "Remdesivir for the treatment of Covid-19 - preliminary report", N Engl J Med (2020)[DOI]
11. Xu Z, "Pathological findings of COVID-19 associated with acute respiratory distress syndrome", Lancet Respir Med, 8, pp.420~422 (2020)
12. Bai Y, "Presumed asymptomatic carrier transmission of COVID-19", JAMA, 323, pp.1406~1407 (2020)
13. Zheng F, "Clinical characteristics of children with coronavirus disease 2019 in Hubei, China", Curr Med Sci, 40, pp.275~280 (2020)
14. CDC COVID-19 Response Team, "Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020", MMWR Morb Mortal Wkly Rep, 69, pp.382~386 (2020)
15. Xu XW, "Clinical findings in a group of patients infected with the 2019 novel coronavirus(SARS-Cov-2)outside of Wuhan, China : retrospective case series", BMJ, 368, pp.m606~ (2020)
16. Liang W, "Cancer patients in SARS-CoV-2 infection : a nationwide analysis in China", Lancet Oncol, 21, pp.335~337 (2020)
17. Rich NE, "Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis", Hepatology (2020)[DOI]
18. Bangash MN, "COVID-19 and the liver : little cause for concern", Lancet Gastroenterol Hepatol, 5, pp.529~530 (2020)
19. Mahmud N, "Declining Cirrhosis hospitalizations in the wake of the COVID-19 pandemic: a national cohort study", Gastroenterology (2020)[DOI]
20. D’Antiga L, "Coronaviruses and immunosuppressed patients : the facts during the third epidemic", Liver Transpl, 26, pp.832~834 (2020)
21. Mehta P, "COVID-19 : consider cytokine storm syndromes and immunosuppression", Lancet, 395, pp.1033~1034 (2020)
22. Qin J, "Perioperative presentation of COVID-19 disease in a liver transplant recipient", Hepatology (2020)[DOI]
23. "Recommendation on COVID-19"[URL]
24. Li G, "Coronavirus infections and immune responses", J Med Virol, 92, pp.424~432 (2020)
25. Gong J, "Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia", MedRxiv (2020)[DOI]
26. Russell CD, "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury", Lancet, 395, pp.473~475 (2020)
27. Xiao F, "Evidence for gastrointestinal infection of SARS-CoV-2", Gastroenterology, 158, pp.1831~1833.e3 (2020)
28. Holshue ML, "First case of 2019 novel coronavirus in the United States", N Engl J Med, 382, pp.929~936 (2020)
29. To KK, "Consistent detection of 2019 novel coronavirus in saliva", Clin Infect Dis (2020)[DOI]
30. van Doremalen N, "Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1", N Engl J Med, 382, pp.1564~1567 (2020)
31. Wang J, "COVID-19 may transmit through aerosol", Ir J Med Sci. (2020)[DOI]
32. "Recommendations for endoscopy units during the COVID-19 pandemic"[URL]
33. "Prevention and management of COVID-19 in healthcare facility"[URL]
34. "Disinfection guidelines to prevent the spread of COVID-19 at public and multi-purpose facilities"[URL]
35. Li G, "Therapeutic options for the 2019 novel coronavirus(2019-nCoV)", Nat Rev Drug Discov, 19, pp.149~150 (2020)
36. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
37. Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses", Sci Transl Med, 9, pp.eaal3653~ (2017)
38. Grein J, "Compassionate Use of remdesivir for patients with severe COVID-19", N Engl J Med, 382, pp.2327~2336 (2020)
39. Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebocontrolled, multicentre trial", Lancet, 395, pp.1569~1578 (2020)
40. Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19", N Engl J Med, 382, pp.1787~1799 (2020)
41. Luo P, "Tocilizumab treatment in COVID-19 : a single center experience", J Med Virol, 92, pp.814~818 (2020)
42. Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)", Clin Infect Dis (2020)[DOI]
43. Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an open-label non-randomized clinical trial", Int J Antimicrob Agents (2020)[DOI]
44. Molina JM, "No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection", Med Mal Infect, 50, pp.384~ (2020)
45. Shen C, "Treatment of 5critically ill patients with COVID-19 with convalescent plasma", JAMA, 323, pp.1582~1589 (2020)
46. against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks(Marmota monax), "Hepatology", 2001, 254~266
47. Seok JI, "Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA", Hepatology, 49, pp.2080~2086 (2009)
48. Tak WY, "Clinical, biochemical, and pathological characteristics of clevudineassociated myopathy", J Hepatol, 53, pp.261~266 (2010)
49. Fang L, "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection", Lancet Respir Med, 8, pp.e21~ (2020)
50. Guo J, "Coronavirus Disease 2019(COVID-19)and cardiovascular disease : a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors", angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection, 2020, pp.9, e016219~
51. Remuzzi A, "COVID-19 and Italy : what next?", Lancet, 395, pp.1225~1228 (2020)

관련 논문AI추천